IV 
115TH CONGRESS 
1ST SESSION 
H. RES. 148 
Expressing support for the designation of ‘‘National Multiple Myeloma 
Awareness Month’’. 
IN THE HOUSE OF REPRESENTATIVES 
FEBRUARY 17, 2017 
Mr. HIGGINS of New York submitted the following resolution; which was 
referred to the Committee on Oversight and Government Reform 
RESOLUTION 
Expressing support for the designation of ‘‘National Multiple 
Myeloma Awareness Month’’. 
Whereas multiple myeloma (or myeloma) is a cancer of plas-
ma cells in the bone marrow and is called ‘‘multiple’’ be-
cause the cancer can occur at various sites in the body; 
Whereas multiple myeloma causes a variety of adverse health 
effects, including a weakened immune system, anemia, 
kidney damage, and bone deterioration; 
Whereas multiple myeloma is the second most common blood 
cancer worldwide; 
Whereas multiple myeloma currently affects more than 
100,000 people in the United States, with about 30,330 
new diagnoses and 12,650 deaths from the disease occur-
ring in 2016, according to the Surveillance, Epidemi-
VerDate Sep 11 2014 
21:43 Feb 17, 2017
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR148.IH
HR148
mstockstill on DSK3G9T082PROD with BILLS
•HRES 148 IH 
ology, and End Results Program of the National Cancer 
Institute; 
Whereas although multiple myeloma has been and continues 
to be most frequently diagnosed among those 65 and 
over, the disease is increasingly being diagnosed in 
younger individuals, including those in their 30s, 40s and 
50s; 
Whereas multiple myeloma is almost twice as likely to occur 
among African-Americans and is one of the leading 
causes of cancer deaths among African-Americans, with 
scientific understanding of the disparity remaining un-
known; 
Whereas although the cause of multiple myeloma remains un-
known, robust research is being performed in the United 
States and internationally into potential genetic, environ-
mental, and other risk factors; 
Whereas additional new drugs and therapies are in the re-
search phase, with patient enrollment in clinical trials 
playing an important role in determining safe and effec-
tive treatments; 
Whereas understanding and treatment of multiple myeloma 
has been greatly furthered by advocacy initiatives pro-
moting awareness, education, research, peer review, and 
collaboration and such efforts are to be highly com-
mended; 
Whereas greater awareness of multiple myeloma among clini-
cians and the public can lead to earlier detection and 
treatment, improving health outcomes and bringing com-
fort to patients and their families; and 
VerDate Sep 11 2014 
21:43 Feb 17, 2017
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR148.IH
HR148
mstockstill on DSK3G9T082PROD with BILLS
•HRES 148 IH 
Whereas March would be an appropriate month to designate 
as ‘‘National Multiple Myeloma Awareness Month’’: Now, 
therefore, be it 
Resolved, That the House of Representatives supports 
the designation of ‘‘National Multiple Myeloma Awareness 
Month’’ to increase public knowledge of the disease and 
advance the vision of finding a cure for multiple myeloma. 
Æ 
VerDate Sep 11 2014 
21:43 Feb 17, 2017
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\HR148.IH
HR148
mstockstill on DSK3G9T082PROD with BILLS